AKEBIA THER
NASDAQ: AKBA (Akebia Therapeutics, Inc.)
Kemas kini terakhir: 11 minit lalu0.524
-0.01 (-1.69%)
| Penutupan Terdahulu | 0.533 |
| Jumlah Dagangan | 1,659,206 |
| Harga / Pendapatan (P/E Ke hadapan) | 28.75 |
| Harga / Jualan (P/S) | 0.550 |
| Harga / Buku (P/B) | 5.47 |
| Julat 52 Minggu |
| Margin Keuntungan | -24.51% |
| Margin Operasi (TTM) | 23.85% |
| EPS Cair (TTM) | -0.210 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 75.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 795.72% |
| Nisbah Semasa (MRQ) | 2.23 |
| Aliran Tunai Operasi (OCF TTM) | -34.81 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 12.96 M |
| Pulangan Atas Aset (ROA TTM) | -4.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Akebia Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Nilai 35% | -0.8 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -0.8 |
| Masa 35% | -2.5 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.5 |
| Purata Bergerak Teknikal info | -2.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.16 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -6.1% |
| Persetujuan Tonggak | ×1.25 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 3.0 |
| Skor Akhir | -1.68 |
|
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.59% |
| % Dimiliki oleh Institusi | 38.96% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Aqr Capital Management Llc | 30 Jun 2026 | 9,151,524 |
| Acadian Asset Management Llc | 30 Sep 2026 | 8,970,363 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 4,273,026 |
| Goldman Sachs Group Inc | 30 Jun 2026 | 3,689,167 |
| Millennium Management Llc | 30 Jun 2026 | 3,196,605 |
| Two Sigma Investments, Lp | 30 Jun 2026 | 2,436,673 |
| Charles Schwab Investment Management Inc | 30 Jun 2026 | 2,300,438 |
| Northern Trust Corp | 30 Jun 2026 | 2,160,365 |
| Fmr Llc | 30 Sep 2026 | 2,120,856 |
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |